Cognition Therapeutics Inc CGTX

Healthcare Biotechnology

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.

NDAQ:CGTX - Post by User

Cognition Therapeutics Inc

Bullboard Posts

(27)
•••

Post by ubiquitousmanon May 20, 2023 1:40pm

161 Views

Post# 35457848

Ok, I will start, stock closed at $2.17 5-19-23-could be ..

interesting. Different take on AD. High risk play but I could make a case for this to
be a $50-$100 stock in 24 months if they can prove efficacy in AD treatment. Stay
tuned. Minute market cap of $60MM, plenty of cash for year or two. Totally ignored
stock.

Bullboard Posts

The 5-Minute Investor Podcast, Ep. 15: Ferroglobe and HPQ Silicon